NCT01683279View on ClinicalTrials.gov

A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 25, 2012

Primary Completion Date

January 7, 2015

Study Completion Date

January 7, 2030

Conditions
B Cell Leukemia
Interventions
BIOLOGICAL

Autologous CD19 CAR+ EGFTt + T cells

Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag

Trial Locations (1)

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER